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Gene expressionEssential to beat-to-beat heart function is the ability for cardiomyocytes to propagate electrical excitation and
generate contractile force. Both excitation and contractility depend on speciﬁc ventricular ion channels,
which include the L-type calcium channel (LTCC) and the connexin 43 (Cx43) gap junction. Each of these
two channels is localized to a distinct subdomain of the cardiomyocyte plasma membrane. In this review,
we focus on regulatory mechanisms that govern the lifecycles of LTCC and Cx43, from their biogenesis in
the nucleus to directed delivery to T-tubules and intercalated discs, respectively. We discuss recent ﬁndings
on how alternative promoter usage, tissue-speciﬁc transcription, and alternative splicing determine precise
ion channel expression levels within a cardiomyocyte. Moreover, recent work on microtubule and actin-
dependent trafﬁcking for Cx43 and LTCC are introduced. Lastly, we discuss how human cardiac disease phe-
notypes can be attributed to defects in distinct mechanisms of channel regulation at the level of gene expres-
sion and channel trafﬁcking. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac
Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Each second and with each heartbeat, millions of individual car-
diomyocytes must synchronously contract to circulate blood and sus-
tain life. Integral to this process is the proper expression of cardiac ion
channels that function together as an integrated biological electrical
system that rapidly conducts the depolarizing current from cell-to-
cell in an organized fashion, and provide the signal that results in
cellular contraction. In the diseased heart, tissue damage as well as
changes in ion channel expression and organization contribute to
both arrhythmias and heart failure (HF), which are the primary
causes of death and disability in the United States. Studies ﬁnd that
adults over 40 years of age have a 20% lifetime risk of developing
heart failure, and 50% of HF patients develop sudden cardiac death
as a result of arrhythmias [1,2]. In the United States, the incidence
of HF is growing to epidemic proportions.
This review focuses on mechanisms that govern the lifecycle and
function of two major cardiac ion channels that are indispensable
for cellular excitability, cell–cell coupling, and excitation-contraction
coupling: the L-type calcium channel (LTCC) and the major cardiac
gap junction protein, connexin 43 (Cx43) [3–7] (Fig. 1). Also, we dis-
cuss in detail a protein which is essential for LTCC trafﬁcking andocyte Biology: Cardiac Pathways
stitute, University of California,
aw).
l rights reserved.delivery, bridging integrator 1 (BIN1). BIN1 is rapidly emerging as a
multifunctional cardiac player beyond its previously understood role
as a membrane scaffold. Lastly, recent advances in understanding of
the role of LTCC and Cx43 expression and trafﬁcking in human heart
physiology and disease will be discussed.
1.1. Connexin 43 is an important cardiac gap junction channel
Gap junctions, comprised of connexin proteins (Cxs), are inter-
cellular channels that form low-resistance pathways allowing for
ions and metabolites up to 1 kDa in molecular mass to ﬂow from
cell to cell. Gap junctions were ﬁrst identiﬁed as electron-dense struc-
tures with a distinct gap of 2–3 nanometers from which their naming
is derived. A gap junction consists of a pair of abutting connexons that
reside in adjacent cell membranes. Each connexon, or hemichannel,
comprises 6 Cxs, which can be homomeric (containing the same Cx)
or heteromeric (containing more than one type of Cx). A heterotypic
gap junction is a pair of connected but different connexons. A total of
20 and 21 connexins have been identiﬁed in the sequenced mouse
and human genomes, respectively, each of which is named according
to their respective molecular mass [8]. All connexins contain four
transmembrane domains. There are two extracellular loops and a cy-
toplasmic loop with the amino- and carboxyl-termini residing in the
cytoplasm.
In the heart, gap junctions electrically couple cardiomyocytes to or-
chestrate action potential propagation [9]. Cardiomyocytes are ex-
tensively coupled via gap junctions containing speciﬁc combinations
of the following connexins: Cx40, Cx43, Cx45, and Cx30.2, which are
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Fig. 1. Regulatory mechanisms of Cx43 and Cav1.2 gene expression and trafﬁcking. In the cardiomyocyte nucleus, Cx43 and Cav1.2 are regulated at multiple levels of gene expression
such as chromatin remodeling, alternative promoter usage, tissue-speciﬁc transcription, and alternative splicing. Once the channel proteins are translated and packaged into ves-
icles, they exit the Golgi and are trafﬁcked toward speciﬁc and distinct domains of the cell surface, in particular the intercalated disk for Cx43 and T-tubules for Cav1.2. This directed
targeting process is dependent on microtubules as well as the actin cytoskeleton machinery. Key proteins that provide speciﬁcity to channel trafﬁcking are highlighted.
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system [10–13]. Cx43 is the most abundant connexin in the ventricular
myocardium. Studies of gap junction permeability have revealed that
homotypic junctions have similar selectivity to monovalent cations,
with Cx43 having a high cation selectivity [14,15]. Moreover, Cx43
channel gating can be regulated by the transjunctional or transmem-
brane voltage, pH, and intracellular Ca2+ concentrations [16–18].
Post-translational modiﬁcation is key for regulating channel assembly,
trafﬁcking, gating, and cell–cell coupling. The Cx43 C-terminus is exten-
sively phosphorylated as the immature protein trafﬁcs through the
endoplasmic reticulum (ER) and the Golgi toward the plasma mem-
brane [19–21].While this review is focused on trafﬁcking of homomeric
connexons consisting of Cx43, it should be noted that Cx26 and Cx32
can be incorporated with Cx43 into heteromeric connexons as early as
translation in the ER or en route to the Golgi apparatus [22–24].
In individual ventricular cardiomyocytes, Cx43 is localized in large
aggregates at the intercalated disc at longitudinal ends of the cell,
where it provides rapid and directed action potential transmission
[25,26] (Fig. 1). Cx43 function is indispensable for normal develop-
ment. Homozygous null mice are perinatal lethal with pulmonary out-
ﬂow tract obstruction [27–29]. Heterozygous mice, with 50% of Cx43
remaining, either have ventricular activation delay and reduced
conduction velocity [30–32] or no conduction slowing [33,34].
Cardiac-speciﬁc conditional deletion models with greater than 50%
Cx43 loss develop increased arrhythmia susceptibility and sudden
cardiac death [35–37]. In general, these studies reveal that ventricular
conduction slowing and arrhythmia susceptibility manifest when
total Cx43 drops to less than 20% in the heart, which correlates with
theoretical predictions [38]. Thus, maintenance of proper Cx43 ex-
pression and localization has a critical role in appropriate electrical
coupling and ventricular function.
1.2. The L-type calcium channel
While connexins electrically couple cardiomyocytes, the mem-
brane ion channel most responsible for calcium entry and excitation-contraction coupling is the LTCC, of which Cav1.2 is the α1C pore-
forming subunit. In response to membrane depolarization by sodium
currents, LTCCs open to allow inward Ca2+ entry during the plateau
phase of the cardiac action potential. The L-type currents (ICa,L) that
are generated initiate calcium-inducedCa2+ release from the sarcoplas-
mic reticulum (SR) via ryanodine receptors, which leads to muscle con-
traction. The Cav1.2 protein is large, consisting of 24 transmembrane
segments organized into four homologous domains [39]. Auxiliary sub-
units of the LTCC include the β subunit, the α2δ subunit, and the γ
subunit which regulate trafﬁcking of the pore forming α1C subunit to
the cell membrane and the voltage dependence of channel gating [40].
Cav1.2 is expressed in the form of multiple splice variants the
brain, lung, smooth muscle, and the heart [41]. Studies show that
the LTCC is critical for cardiac development and function. Mice with
global deletion of the Cacna1c gene have abnormal embryonic cardiac
function and morphogenesis [42]. Moreover, smooth muscle-speciﬁc
LTCC inactivation results in reduced arterial blood pressure, loss of
depolarization-induced contraction in the tibialis arteries, and lethal-
ity one month after gene ablation [43]. Cardiac-speciﬁc Cav1.2 dele-
tion in adult mice results in reduced myocardial contractility and
lethality [44]. Heart function and ICa,L density are unaltered in hetero-
zygous mice with cardiac-speciﬁc Cav1.2 deletion, suggesting that
adaptive mechanisms exist to maintain channel function by compen-
sating for some loss in Cav1.2 biosynthesis [44]. However, in response
to pressure overload and isoproterenol stimulation, heterozygous
mice develop a decrease in ICa,L, reduced cardiac function, and heart
failure [45]. Recently, we found that the molecular adaptor protein
BIN1 functions to target LTCCs to specialized T-tubule structures
within the cardiomyocyte plasma membrane, as discussed below.
1.3. BIN1: a molecular adaptor with heart
BIN1, also known as amphiphysin 2, belongs to the Bin1-
Amphiphysin-Rvs (BAR) domain superfamily which is comprised of
adaptor proteins that participate in multiple cellular processes in
many organs, including the heart [46]. BIN1 is characterized by a
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Fig. 2. Connexin expression regulation in the cardiac conduction system. Illustration
depicting antithetical regulation of Cx40 and Cx43 at the molecular level. Irx3 antago-
nizes Nkx2.5-dependent activation of Cx43 transcription and indirectly activates Cx40
expression. The lower panel is a graphic model of how altered expression of both
connexins can delay propagation of the depolarizing impulse and slow ventricular ac-
tivation. RBB, right bundle branch; LBB, left bundle branch; PF, Purkinje ﬁbers.
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nization, as well as a middle region with alternatively-spliced exons
encoding either a phosphoinositide interacting motif (PI) in skeletal
muscle, or a clathrin binding domain (CLAP) in the brain [47,48].
The C-terminus contains an alternatively spliced Myc-binding do-
main (MBD), and a Src homolog 3 (SH3) domain that expands the
BIN1 binding partner repertoire through protein-protein interactions.
For example, the BIN1 SH3 domain binds neuronal dynamin and com-
ponents of the skeletal sarcomere such as α-actin and myosin [49,50].
BIN1 has been explored in cancer cells where it inhibits c-Myc-
mediated cell transformation and promotes apoptosis [47,49,51–54].
Several tissue-speciﬁc Bin1 splice variants have been identiﬁed that
participate in cell growth and migration, synaptic vesicle endocytosis,
as well as T-tubulogenesis and sarcomere development in skeletal
muscle [47,50,55]. Targeted global deletion of Bin1 results in peri-
natal lethality in mice, which is characterized by hypertrophic dilated
cardiomyopathy with thickened ventricular walls and densely packed
cardiomyocytes [56,57]. BIN1 has recently been found to target LTCCs
to cardiac T-tubules to ensure appropriate calcium signaling for prop-
er excitation-contraction coupling [4]. In human heart failure, BIN1 is
shown to be reduced, indicating that it is critical for cardiac function
[4,5], as discussed below.
2. Regulation of cardiac ion channel expression
Gene expression is an early primary step in the generation of func-
tional cardiac ion channels, which includes transcription, RNA splicing
and processing, as well as post-translational modiﬁcation. Examples of
recent studies on the precise control of Cx43 [3,58–61], LTCC [62–74],
and BIN1 [48,53,75,76] expression are discussed below.
2.1. Cx43: a rich protein diversity is generated from a single gene
Changes in Cx43 expression level and region-speciﬁc patterning
can alter cell–cell coupling and the path of excitation spreading
throughout the heart. Cx43 resides on mouse chromosome 10 and
human chromosome 6, and has a relatively simple genomic structure
of only two exons. The ﬁrst exon encodes a 5′-untranslated region
(5′-UTR) while the second exon contains the entire coding region
plus the 3′-UTR [58,61]. Interestingly, four additional exons have
been reported, all of which code for novel 5′-UTRs [59]. In addition
to the canonical promoter, two alternative promoter regions were
found to be conserved in mice and rats. The alternate promoters lie
within exon 1A and the intron immediately upstream of exon 1C.
While the canonical promoter is active throughout the heart, the
exon 1A promoter is active only in the atrium and septum but not
the ventricle. The intronic promoter is utilized in the ventricles only.
With these additional regulatory elements, a total of nine unique tran-
scripts are detectable that only differ in their 5′-UTR to dictate transla-
tional efﬁciencies of each corresponding mRNA. Thus far, no alternate
5′-UTRs have been detected in humans.
Transcriptional control of Cx43 expression can be mediated
by homeobox factors. Members of the homeobox family, which is
characterized by a 60 amino acid homeobox DNA-binding domain,
function within a transcriptional complex with other co-factors to
switch gene cascades on or off in various tissues [60,77]. Nxk2.5 is a
homeodomain-containing transcription factor with highly conserved
function in heart development, the loss of which results in progres-
sive conduction defects and left ventricular dysfunction [78–83]. The
Iroquois homeobox gene 3 (Irx3) encodes a transcription factor charac-
terized by a highly conserved DNA-binding homeobox of the three
amino acid loop extension (TALE) superclass [84]. Nkx2.5 and Iroquois
genes play conserved roles during embryogenesis, and function as ei-
ther transcriptional activators or repressors depending on the cellular
context [85–87].We recently determined that Irx3 is required for normal connexin
expression in the cardiac His-Purkinje network, which functions to
tightly control electrical excitation spread and ventricular activation
[3]. The His-Purkinje network is extensively coupled via gap junctions
containing speciﬁc combinations and patterns of mainly Cx40, and
Cx43 [10–13]. We found that Irx3 is expressed in the developing con-
duction tissue, and that it is required for establishing efﬁcient impulse
conduction by antithetically regulating Cx40 and Cx43, whereby
Irx3 indirectly activates Cx40 while directly repressing Cx43 tran-
scriptional activation by Nkx2.5 (Fig. 2). Irx3 loss-of-function resulted
in reduced Cx40 expression throughout the conduction tissue, and
ectopic Cx43 expression in the proximal bundle branches. These
changes in connexin expression resulted in abnormal cell–cell cou-
pling, disruption of rapid and coordinated spread of ventricular exci-
tation, as well as right bundle branch block. Together, these studies
reveal an important role for Irx3 in the tight regulation of connexin
expression, and provide insight into a regulatory pathway that can
go awry leading to the development of cardiac arrhythmias.
2.2. Alternative splicing and auto-regulation of LTCCs
LTCCs have diverse roles in regulatingmembrane excitability,mus-
cle contraction, and gene expression. Cav1.2 is encoded by the Cacna1c
gene located on chromosome 6 in the mouse and chromosome 12 in
humans. Mutations in CACNA1C lead to Brugada syndrome and short
QT syndrome [88,89]. The core rat Cacna1c promoter contains binding
sites for tissue-speciﬁc and ubiquitous transcription factors, along
with cAMP and hormone response elements [69]. Studies in humans
and rats uncovered that Cacna1c contains two alternative promoters
through differential usage of the ﬁrst exon that yields a cardiac-
enriched isoform, and another that predominates in the vasculature
and other muscle tissues [65,66,68].
A key mechanism for the wide repertoire of Cav1.2 protein iso-
forms is alternative splicing of the pre-mRNA. Splicing is regulated
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splice sites of target pre-mRNA [90]. This dynamic process is essential
for producing multiple distinct protein isoforms from a single gene,
and is an important layer of gene regulation in the heart. Several
alternative splicing switches, comprised of key RNA-binding splicing
regulators and their target effector genes encoding transcription
factors, the sarcomere, and the E–C coupling machinery, have
been determined to govern cardiac development and physiology
[70–74,91–96].
In humans, CACNA1C contains 55 exons, of which 19 exons are al-
ternatively spliced [71]. It was recently demonstrated that splicing of
exons 9* and 33 is controlled by the Fox family of splicing regulators
during cortical development [70]. Exon 9* inclusion into the mature
transcript progressively decreased while exon 33 inclusion increased
during differentiation. These changes conferred distinct electrophysi-
ological properties on the LTCC, creating a shift toward a more posi-
tive depolarizing potential for activation and inactivation. Moreover,
the mutually exclusive exons 8 and 8a encode alternative forms of
the transmembrane segment 6 within domain 1 of Cav1.2, and have
been implicated in tissue-speciﬁc dihydrophyridine sensitivity of
LTCCs in cardiac versus vascular smooth muscle [72]. Mutations in
these exons also lead to Timothy syndrome, which is characterized
by structural and conduction defects in the heart [73,74].
An interesting example of Cav1.2 regulation is that segments of its
C-terminus are capable of auto-regulation at the level of channel activ-
ity and gene transcription. Studies in neurons and cardiomyocytes
suggested that Cav1.2 is proteolytically cleaved to generate a truncated
channel and a C-terminal fragment (CCt) [97,98]. The CCt was found
to re-associate with the truncated channels at the plasma mem-
brane to modulate their activity [98–101]. Recent studies showed that
Cav1.2 also functions to couplemembrane excitation to gene expression
through its CCt, which localizes to the nucleus to regulate transcription
[62,63,67]. In neurons and heterologous expression systems, a ~300
amino acid CCt fragment was shown to localize to the nucleus in re-
sponse to calcium signaling to regulate transcription of gap junction
proteins such as Cx31.1, potassium channels, the sodium calcium ex-
changer Scl8A1, and a number of signaling proteins [67]. Studies of
the CCt in cardiomyocytes revealed that it auto-regulates Cav1.2 expres-
sion as a transcriptional repressor [63]. An essential role for the CCt in
the cardiovascular system was demonstrated in two mouse models
with either a targeted truncation at Gly-1796 [64], or at Asp-1904
[102]. These mice were characterized by reduced cell surface Cav1.2 ex-
pression, cardiac failure, and perinatal lethality.
Given the importance of LTCC function in initiating the excitation-
contraction coupling that drives cardiac contraction, it is not surpris-
ing that the biogenesis and function of the Cav1.2 α1C pore-forming
subunit is tightly regulated by multiple mechanisms. The ﬁnding
that the CCt functions as a transcription factor with multiple targets,
including the Cacna1c gene for feedback inhibition, positions Cav1.2
as an elegant example of how membrane events are communicated
to the nucleus to maintain ion channel homeostasis and normal cellu-
lar function.
2.3. Alternative splicing of Bin1
Bin1 was intially identﬁed as a binding partner for the proto-
oncogene c-Myc [54]. In the heart, Bin1 aids in the delivery of LTCCs
to T-tubules [4]. Similar to the Cav1.2 protein, Bin1 expression is also
tightly regulated by a number of mechanisms, of which alternative
splicing is becoming better understood. Members of the BAR family, in-
cluding BIN1, function in critical cellular processes such as transcription,
endocytosis, tumor suppression, apoptosis and cell growth control [46].
The Bin1 gene contains 20 exons in both mice and humans, many
of which show tissue-speciﬁc alternative splicing. For example, exon
11 encodes a phophoinositide-binding (PI) domain, which when
inlcuded into the mature mRNA, generates a BIN1 isoform thatinduces tubular invaginations during skeletal T-tubule biogenesis
[103–105]. A switch in subcellular organization and splicing of Bin1
variants has been detected for C2C12 mouse myoblast differentiation
[106]. While Bin1 variants predominantly localize to the nucleus of
undifferentiated myoblasts, they are found as a ﬁlamentous network
in the cytoplasm of terminally differentiated myotubes. The signiﬁ-
cance of Bin1 function has been recently demonstrated in human dis-
ease. Coding sequence mutations and abberant splicing were shown
to give rise to centronuclear myopathies and myotonic dystrophy
[75,107,108]. Whether additional mutations and abberant Bin1 splic-
ing events contribute to cardiac disease remains to be tested.
Alternative splicing of Bin1 in the heart is not well studied. In other
systems, direct binding of the Bin1 SH3 domain to a proline-richmotif
in c-Myc was shown to inhibit c-Myc-mediated cell transformation
and promote apoptosis [54,109]. Abberant inclusion of Bin1 exon 13
generates a Bin1+13 variant incapable of binding and inhibiting
c-Myc, thus promoting unchecked cell proliferation and tumorigene-
sis [48]. Structural studies later showed that Bin1 exon 13 encodes a
proline-rich motif that preferentially binds to the Bin1 SH3 domain
to prevent c-Myc binding and inhibition [110]. Thus, alternative splic-
ing of Bin1 in cancer cells acts as a switch that governs c-Myc-
dependent cellular activities. Several transcription factors including
c-Myc have been shown to maintain the balance between prolifera-
tion and differentiation during cardiac development [111–116].
Whether alternative splicing of Bin1 plays a role in cardiomyocyte
maturation and function remains to be tested.
3. Directed targeting of cardiac ion channels
Post transcription and translation, the proteins that form cardiac
ion channels are modiﬁed and usually oligomerize in the ER and
Golgi apparatus where they are inserted into membrane vesicles for
delivery to the plasma membrane. The cytoskeleton transports the
vesicles to the plasma membrane, with most studies focusing on the
role of microtubule-based forward transport [117–122]. A critical as-
pect of forward transport is localization to membrane subdomains. It
is entirely possible that channels may be delivered to random regions
of the plasma membrane, only to then laterally diffuse within the
membrane to their appropriate subdomain [118]. However, the tem-
poral and stochastic inefﬁciency of random channel insertion, togeth-
er with unexplained mechanisms of subsequent lateral localization,
other than chance interaction with a subdomain-speciﬁc anchor pro-
tein, suggests that speciﬁcity of delivery from the Golgi to the surface
submembrane may also occur. We have found the Cx43 gap junctions
are localized to cell–cell bordered regions by a combination of the
plus-end-tracking proteins EB1 and p150 (Glued) at the end of micro-
tubules, and the adherens junction membrane complex, which cap-
tures the EB1-tipped microtubules, to allow for Cx43 hemichannels to
be ofﬂoaded onto adherens junction-containing membrane [6,7,119]
(Fig. 1). This directed targeting paradigm of ion channel delivery may
be generalizable to other cardiac ion channels and explored in terms
of other cytoskeletal elements and anchor proteins [123], as we discuss
below.
3.1. Trafﬁcking of Cx43
Data exist formultiple, but not incompatible,models of Cx43 trafﬁck-
ing to cell–cell borders of cardiac intercalated discs [6,9,118,119,121].
There is almost universal agreement that microtubules help deliver
Cx43 to the plasma membrane. A landmark series of two papers in
2002 found evidence that newly formed Cx43 appears at the perimeter
of the Cx43 plaques and then diffuses into central plaque regions
[118,121]. Taken together with microtubule delivery, the model devel-
oped that Cx43 hemichannels are inserted into the general plasma
membrane, rapidly diffuse to the edge of dense plaques, and then
more slowly diffuse into the plaque center. Subsequent to these studies,
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into plaques, and that membrane ﬂuidity exits within the plaque region
[119,124]. It has also been found that the plaques are not necessarily in-
ternalized from the center, but different segments of plaque can be in-
ternalized at any time [124], and full plaque internalization can occur
in one step [125]. More recently, it has been found that Cx43 occurs in
regions surrounding Cx43 plaques, the “perinexus”, at higher density
than in general membrane where Cx43 proteins may interact with scaf-
folding proteins andother ion channels [123,126]. These studies are pro-
viding evidence that the gap junction plaque and surrounding regions
are highly dynamic with complex behavior of targeted insertion and
internalization.
Given the low density of Cx43 hemichannels in membrane well
away from Cx43 plaque regions, and the technical difﬁculty of
distinguishing Cx43 inserted in membrane from submembranous
and still cytoplasmic collections of protein, we have had difﬁculty
ﬁnding studies that can quantify the lateral diffusion coefﬁcient of
membrane-bound Cx43. It may be that free hemichannels rapidly dif-
fuse within the plasmamembrane prior to stopping at plaque regions,
but direct evidence for this phenomenon is lacking. Our directed
targeting paradigm is based on the observation that de novo intracel-
lular Cx43 hemichannels can arrive directly in the gap junction plaque
region. The hemichannels are targeted to plaque regionswith speciﬁc-
ity obtained from the hemichannel protein (Cx43), microtubule
plus-end tracking proteins EB1 and p150 (Glued), and a membrane
anchor (adherens junction structure)[119]. By this model, the dynam-
ic microtubule highways are anchored, and terminate at adherens
junction structures, allowing directed delivery of Cx43 hemichannels
to adherens junction-containing membranes. It is probable that once
inserted into plaque regions, local hemichannel diffusion occurs with-
in the plaque, and between the plaque and the plaque perinexus.
While most studies of Cx43 forward trafﬁcking focus on themicro-
tubule cytoskeleton, the actin cytoskeleton is also involved in delivery
of membrane proteins and ion channels. Dye transfer studies revealed
the dependence of Cx43 insertion into plaque on actin, as tested by
pharmacologic actin disruption and anti-actin antibodies [127,128].
Actin is also important for Cx43 plaque internalization, although we
recently found that when internalization is blocked, forward delivery
is still actin-dependent [7] (Fig. 1). Furthermore, a remarkably greater
than 80% of post-Golgi cytoplasmic Cx43 is slow moving or stationary
and actin-associated. These ﬁndings indicate that microtubules work
in concert with actin to deliver Cx43 to the plasma membrane. It may
be that post-Golgi Cx43 vesicles exist in actin-associated reservoirs
within the cytoplasm, waiting for either the right microtubule to per-
mit membrane delivery or mass acute delivery in the case of a meta-
bolic stress.
Histone modifying enzymes such as histone deacetylases (HDACs),
which modiﬁes histone tails to repress gene transcription, were found
to regulate Cx43 expression inmouse embryonic stem cells [129]. Inter-
estingly, HDAC inhibitors have been tied to trafﬁcking and post-
translational modiﬁcation of Cx43 in the heart. For instance, prolonged
treatment of themdxmouse model of Duchenne's Muscular Dystrophy
with HDAC inhibitors prevented ventricular arrhythmias, and reversed
conduction defects [130,131]. These changes were accompanied by a
restoration of Cx43 distribution at the intercalated disk from a patho-
logical lateralized membrane pattern, without changes in Cx43 gene
expression. It was later revealed that Cx43 localization to the intercalat-
ed disk and normal cell coupling are dependent on the degree of
Nε-lysine acetylation of Cx43 maintained by a balance of histone
acetyltransferases and deacetylases [132]. These studies and others
have revealed multiple new functions for proteins previously known
to be associated with gene expression regulation in directly affecting
connexin trafﬁcking.
Cx43 internalization is also a keymechanism that ensures dynamic
cell surface channel expression and cell–cell coupling. Cx43 internali-
zation is regulated by a number of post-translational modiﬁcations ofits intracellular C-terminus, of which casein-kinase-dependent phos-
phorylation has been shown to affect gap junction formation, remod-
eling, as well as arrhythmic susceptibility [133]. Moreover, protein
kinase C stimulation promotes channel internalization through Cx43
ubiquitination [134]. Internalization of either Cx43 hemichannels
or intact gap junctions has been observed. In the latter case, large
double-membrane structures known as annular gap junctions are pro-
duced before being degraded by the lysosome and proteasome. Al-
though gap junction recycling at the cell surface has been identiﬁed
for cell cycle progression in speciﬁc cell lines [135], whether this traf-
ﬁcking mechanism is conserved in cardiomyocytes remains to be
tested.
3.2. LTCC trafﬁcking
T-tubule invaginations of ventricular cardiomyocyte plasmamem-
brane are enriched with L-type calcium channels (Fig. 1). This enrich-
ment is necessary for calcium-induced-calcium-release with nearby
ryanodine receptors, which is important for beat-to-beat excitation-
contraction coupling in the heart. Trafﬁcking of the LTCCs is not as ex-
tensively studied as that of Cx43, probably due to a combination of the
large size of the α1C subunit, the difﬁculty of manipulating cardio-
myocytes with T-tubules in culture, the lack of channel enrichment
on the plasmamembrane thatmakes immunochemistry detection dif-
ﬁcult, and the large number of auxiliary subunits. These auxiliary sub-
units enhance surface LTCC expression by promoting Cav1.2 export
from the ER andmaintenance of the channel once in the plasmamem-
brane [136–138].
Despite the necessary localization of L-type calcium channels to
T-tubules, until recently it was not understood how this localization oc-
curs. In 2010 we found that cardiac LTCCs adhere to the directed
targeting paradigm [4]. In particular, the membrane scaffolding protein
BIN1 was found at cardiac T-tubules and provided a membrane anchor
that attaches dynamicmicrotubules, allowing delivery of LTCCs directly
to T-tubule membrane regions (Fig. 1). Using HL-1 cells that express
LTCCs but do not form T-tubules, and non-muscle cell lines that do
not contain either LTCCs or T-tubules, we found that exogenous BIN1
caused formation of deep invaginations in cell membrane regions
enriched with Cav1.2, suggesting that BIN1-containing membrane is
sufﬁcient to recruit LTCCs. To test the possibility that BIN1 serves as
an anchoring site for microtubules on which LTCCs are trafﬁcked, we
tracked growing microtubules extending toward BIN1 clusters and
found that microtubule plus-ends pause and associate with BIN1 clus-
ters at the cell periphery. Moreover, we determined that the non-BAR
cytoskeleton anchoring domain of BIN1 is required for this activity as
truncation mutants lacking this domain failed to cluster Cav1.2 at cell
surface invaginations. The microtubule plus-end tracking protein that
may aid in microtubule anchoring to BIN1, analogous to EB1 binding
to adherens junctions [6,119], has not yet been identiﬁed.
4. Human disease implications
Heart failure is a growing epidemic with a prevalence of 5,700,000,
annual incidence of 550,000, and annual mortality of 300,000 in the
United States [1]. Disease progression is characterized by extensive
tissue remodeling and abnormal signaling that results in altered ex-
pression of cardiac ion channels [139,140]. As discussed above, Cx43,
and the LTCC along with its adaptor protein BIN1 are important for
normal cardiac development and function. Altered expression levels
and plasmamembrane distribution of Cx43 and LTCC lead to abnormal
cellular communication and excitation-contraction coupling, contribut-
ing to lethal arrhythmias and heart failure. Understanding of the basic
regulatory mechanisms governing channel biogenesis, trafﬁcking, and
membrane organization are likely to yield new possibilities for future
therapeutic intervention.
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Mutations in GJA1, which encodes connexin 43, can cause
oculodentodigital dysplasia, a disease affecting multiple organs and
in rare cases are associated with cardiac abnormalities and sudden
death [141]. Other GJA1 mutations are associated with atrial ﬁbrilla-
tion [142,143]. Moreover, a recent study showed that two novel
missense mutations in the GJA1 coding sequence are linked to hetero-
geneous gap junction loss and sudden infant death [144]. The E42K
and S272P mutations resulted in cell–cell uncoupling via trafﬁcking-
independent and -dependent mechanisms, respectively.
Aberrant changes in Cx43 expression level and trafﬁcking can also
alter cell–cell coupling and impair heart function. Many types of ven-
tricular remodeling that occur in humans due to cardiac overload are
characterized by changes in the expression and distribution of
connexin 43. Myocardial infarction studies revealed decreased Cx43
at the intercalated disc, and lateralization of remaining channels in
the infarct boarder zone [145–147]. Altered gap junction plaque size
exists in most forms of heart failure where changes in the cellular dis-
tribution of Cx43 affect the spread of excitation in the heart, which
can be arrhythmogenic. More recent studies have explored the mech-
anisms of altered Cx43 distribution in disease.
Reduced cardiac cell–cell coupling in ischemic and non-ischemic
hearts is strongly associated with Cx43 dephosphorylation, which is
generally inferred from Western blot band shifts and phospho-
speciﬁc antibodies. For instance, Cx43 dephosphorylation leads to
cell–cell uncoupling in the setting of ischemia which can be rescued
by direct suppression of Cx43 dephosphorylation [148,149]. The spe-
ciﬁc Cx43 residues that undergo post-translational modiﬁcation
during disease are still being explored and there is likely a delicate bal-
ance of disease related phosphorylation and dephosphorylation on the
Cx43 C-terminus. In a recent elegant study it was found that inhibiting
three speciﬁc casein kinase sites (S325/S328/S330) from dephosphor-
ylation protected cardiomyocytes from Cx43 remodeling and arrhyth-
mias during ischemia. It is not known whether diminished cell–cell
coupling is a result of increased rate of plaque internalization, or di-
minished rate of Cx43 delivery, or both. We recently found that hearts
with end-stage ischemic cardiomyopathy were characterized by spe-
ciﬁc disruption of the cytoskeleton based Cx43 forward trafﬁckingma-
chinery without changes in total expression of the protein [6].
Internalization of Cx43 is clathrin dependent [125], and may also
involve zonula occludens-1 (ZO-1), which is a 220 kDa scaffolding
protein that tethers transmembrane proteins such as connexins di-
rectly, or via associated adaptor proteins, to the cytoskeleton [150].
ZO-1 associates with Cx43 via its second PDZ domain at the perimeter
of the gap junctional plaque [151–154]. In patients with end-stage
congestive heart failure due to idiopathic dilated cardiomyopathy
(DCM) and ischemic cardiomyopathy (ICM), decreased Cx43 expres-
sion at the cell surface is accompanied by increased association with
ZO-1 [155]. These studies suggest that ZO-1 may regulate cell surface
gap junction availability by promoting Cx43 endocytosis.
4.2. Functional signiﬁcance of the LTCC and BIN1 in the human heart
Calcium inﬂux in the working myocardium, which critically de-
pends on the α1C pore-forming Cav1.2 subunit, plays a central role
in converting electrical impulses into mechanical activation of the
contractile machinery. Gain-of-function mutations in Cav1.2, which
cause near complete loss of voltage-dependent channel inactiva-
tion and calcium overload in multiple tissues, are linked to Timothy
Syndrome [73,74]. Interestingly, the disease-causing mutations,
G406R and G402S, were found within exons 8 and 8a, which are alter-
natively spliced in a mutually exclusive fashion and are present in dif-
ferent relative amounts in various tissues. It was suggested that the
multitude of severities of symptoms across multiple organs reﬂects
tissue-speciﬁc expression of splice variants. In patients with hypertrophicheart failure, aberrant splicing of the mutually exclusive exons 31 and 32
was detected such that re-expression of the fetal exon contributed to
disease progression [156].
Loss-of-function mutations in Cav1.2 in patients with Brugada syn-
drome are characterized by a short QT interval and sudden cardiac
death [88,89]. When missense mutations at G490R and A39V were
co-expressed with other LTCC subunits in CHO cells, a clear reduction
of ICa,L was observed. Confocal microscopy studies revealed that chan-
nel trafﬁcking was unaffected. Thus, it was hypothesized that the
G490R mutation, which is located in a linker region, interferes with
β subunit binding to the channel to affect current density. Another
study revealed that a V2041I mutation in the C-terminus also reduces
ICa,L amplitude by decreasing channel conductance and altering cur-
rent inactivation [88].
Abnormal E-C coupling, resulting from deregulation at the onset of
Ca2+ inﬂux through the T-tubule network, is increasingly implicated
in heart failure progression and sudden cardiac death. Heart content
of Cav1.2, typically analyzed by biochemical assay of heart muscle ly-
sates, is not altered in failing hearts [5]. However, while we recently
conﬁrmed that total cellular Cav1.2 content is unchanged in heart fail-
ure, we also found that the channels are internalized [5]. Testing the
forward trafﬁcking machinery of LTCCs in failing hearts, we found
that human heart failure involves a reduction in BIN1 at both the
protein and mRNA message level, implying the reduction is at the
level of gene expression. Subsequent studies in adult cardiomyo-
cytes conﬁrmed that decreased BIN1 reduces forward trafﬁcking of
LTCCs, also diminishing intracellular calcium transients (in isolated
cells and zebraﬁsh hearts) and contractility (of zebraﬁsh hearts).
Recent rat studies conﬁrmed that BIN1 is decreased in failing hearts
and recovers with successful treatment [157]. It is therefore possible
that reduced contractility of progressively failing hearts can be traced,
in part, to decreased transcription of BIN1. Understanding the regula-
tion of BIN1 expression is currently an active part of our laboratory
focus.
The potential for BIN1 as a blood available biomarker for arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) was also recently
identiﬁed [158]. ARVC is a primary myocardial disorder with a high
incidence of ventricular arrhythmias [159]. In a retrospective study
of 24 patients, plasma BIN1 predicted cardiac function status and in-
cidence of ventricular arrhythmias. BIN1 has high speciﬁcity and sen-
sitivity in distinguishing ARVC patients with severe disease from
those with milder symptoms. In addition, BIN1 levels correlated in-
versely with disease progression in serial blood draws, and predicted
future arrhythmias in patients without severe heart failure with 82%
accuracy [158]. Current studies are focused on why BIN1, which is
an intracellular yet membrane attached protein, is also available in
the blood.
5. Concluding remarks
In this review we highlight recent insights into the regulation of
the cardiac ion channels Cx43 and LTCC, which are important for cel-
lular excitation, electrical coupling, and contractility. A rich array of
mechanisms has been identiﬁed that govern the dynamic lifecycle
of these channels from gene expression in the nucleus to translation
and targeting to organized subdomains on the cardiomyocyte surface.
Future explorations of the multilayered regulation of cardiac ion
channel biogenesis and trafﬁcking will provide new insights and
new targets to correct altered ion channel function in disease.
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